Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $3.5M | $1.7M | $1.1M | $268.0K | $192.0K | $103.0K | $41.0K |
| Cost of revenue | $19.1M | $33.7M | $19.3M | $16.4M | $48.5M | $49.8M | $43.6M | $36.2M |
| Gross profit | −$17.4M | −$30.1M | −$17.6M | −$15.3M | −$48.2M | −$49.6M | −$43.5M | $41.0K |
| Gross margin | -1006.1% | -859.9% | -1031.4% | -1429.7% | -17979.5% | -25850.5% | -42197.1% | 100.0% |
| R&D | $19.1M | $33.7M | $19.3M | $16.4M | $48.5M | $49.8M | $43.6M | $36.2M |
| Operating income | −$22.8M | −$36.7M | −$24.9M | −$23.2M | −$56.7M | −$58.3M | −$52.1M | −$56.2M |
| EBITDA | −$22.7M | −$36.7M | −$24.7M | −$23.2M | −$56.5M | −$53.9M | −$52.1M | −$56.2M |
| Net income | −$22.7M | −$36.4M | −$24.7M | −$23.1M | −$56.6M | −$62.6M | −$51.8M | −$56.2M |
| Net margin | -1314.6% | -1037.3% | -1447.0% | -2159.1% | -21125.7% | -32616.7% | -50336.9% | -137170.7% |
| EPS (diluted) | -10.03 | -12.74 | -6.96 | -4.13 | -7.45 | -7.09 | -2.77 | -1.42 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $186M | $1.13 | $1.13–$1.13 | 1 |
| 2027 | $915M | $6.17 | $6.17–$6.17 | 1 |
| 2028 | $384M | $2.27 | $2.27–$2.27 | 1 |
| 2029 | $482M | $2.78 | $2.78–$2.78 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CKPT.
No tracked institution reports a position in CKPT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-12-06 | 1-for-10reverse |
No one on the platform has traded CKPT yet.
| $449M |
| — |
| ORTXOrchard Therapeutics plc | $16.70 | +0.30% | $380M | — |
| RVNCRevance Therapeutics, Inc. | $3.65 | +0.00% | $381M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 983.6× sales vs its 752.5× historical median P/S.
Fair value ≈ $3.26 · price $4.26 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CKPT Unlike the US, there is no fixed date for drug approvals in Europe. This is due to built in "clock stops" during the evaluation process. Typically, most drugs get approved around 1 year after positive validation. The two year deadline for the CVR is protection in case the approval takes longer than usual or runs into any sort of delay. But if they do not run into any serious delays, then we may see UNLOXCYT approval by next summer.
View on StockTwits ↗$CKPT CHMP has now begun evaluating UNLOXCYT (Cosibelimab) for approval in Europe. Start of evaluation is May 21, 2026. This is the date the UNLOXCYT MAA received positive validation. The $0.70 CVR will payout if UNLOXCYT is approved within 2 years (by May 21, 2028) and the approved dose is once every 3 weeks. You can confirm the start date here. Download the 'Applications for new human medicines under evaluation' for June 2026: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
View on StockTwits ↗$CKPT I am guessing Sun are gonna wait it out … and not have to pay up
View on StockTwits ↗$CKPT Sun has to submit UNLOXCYT's MAA in Europe by May 30, 2026.
View on StockTwits ↗$CKPT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.
View on StockTwits ↗$MIST Was anyone here in $CKPT ? I'm getting a very very similar vibe here.
View on StockTwits ↗$CKPT Hopefully they will submit for EMA approval soon. Surprised they will only start commercialization in 2026 🤔 https://trial.medpath.com/news/557f3510f2173f9e/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma?__cf_chl_tk=Gz1CHGQt.jjB.jh7FzdQTyB6iASXP3_xJSwaC3zJQGM-1764726181-1.0.1.1-gPnmeEjeSTWUM7e02H8tYWStLS00Lz8mKq.lKKxsWXQ
View on StockTwits ↗$ITRM this time last year I got a long awaited but underwhelming buyout for $CKPT. Hoping we can get one here soon for a couple bucks at least.
View on StockTwits ↗$ITRM I am getting $CKPT PTSD… Still bullish but sometimes the lack of announcements of any short get on my nerves.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.